artemis-platform
(2)
Eureka Therapeutics, Inc.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
Cheng Liu
Cheng Liu is the founder, President, and CEO of Eureka Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California. A molecular cell biologist trained at UC Berkeley and Peking University, Liu invented a novel class of TCR mimic antibodies that allow engineered T cells to recognize intracellular tumor antigens - a major challenge in treating solid tumors. Since founding Eureka in 2006 after a decade at Chiron/Novartis, he has built a pipeline of ARTEMIS T-cell therapies targeting liver cancer, multiple myeloma, and neuroblastoma, with the company's ECT204 program earning FDA RMAT Designation in January 2026 - one of the highest-priority designations the FDA gives to regenerative medicine therapies. Eureka has raised over $168 million in total funding and holds more than 500 patents worldwide.